FoundationOne Liquid CDx reports >300† genes and is able to detect both novel and known variants, including four classes of genomic alterations (base substitutions, insertions or deletions, copy number alterations and gene rearrangements), genomic signatures
(MSI,‡ bTMB) and Tumour Fraction, to provide prognostic, diagnostic and predictive insights that inform research or treatment  decisions for individual patients across all solid tumours.^1,2

Assesses all four main classes of genomic alterations* in >300† cancer-related genes, including guideline-recommended genomic alterations associated with available targeted therapies in all solid tumours.^1,2,4–11

The FDA-approved liquid biopsy service that reports both MSI^‡ and bTMB, pan-tumour biomarkers that may help inform eligibility for immunotherapy.^{1–3,19–27}

High sensitivity and specificity^¥ for key genomic alterations, MSI^‡ and bTMB across all solid tumours.^1,2

Reports Tumour Fraction as a measure of the likelihood of detecting genomic alterations in the liquid biopsy sample.^1,2

FoundationOne Liquid CDx requires only two tubes of blood from a single blood draw (2 x 8.5 mL whole blood) and has a turnaround time of less than 2 weeks from receipt of the sample at our laboratory to report, thereby allowing informed treatment decisions to be
made faster.^1,16
 

This may help reduce distress that patients may experience from long waiting times for scheduling a biopsy and receiving the results associated with tissue-based testing.^12–15

FoundationOne Liquid CDx may also help reduce requirements for healthcare infrastructure and resources compared with tissue-based testing.²⁸

Like FoundationOne CDx, FoundationOne Liquid CDx is based on an analytically and clinically validated, FDA-approved, comprehensive platform and bioinformatics workflow.^{¶1–3,17,18,29}

FoundationOne Liquid CDx covers guideline-recommended, and other clinically relevant genomic alterations and signatures^‡ 
for NSCLC, breast, ovarian and prostate cancer.^{1,2,4–11,19–25,32–37}

Our previous blood-based comprehensive genomic test demonstrated clinical utility for treatment selection at diagnosis in metastatic NSCLC in BFAST (Blood First Assay Screening Trial), a global, prospective cohort study.^29,38

FoundationOne Liquid CDx sequences circulating cell-free DNA (cfDNA), which can originate from the primary as well as metastatic tumour sites, thereby capturing the disease heterogeneity across the body as the disease evolves.^1,2,14,15

Approved targeted therapies and immunotherapies for the patient’s gene alterations and genomic signatures are ranked alphabetically within NCCN therapy categories (for additional information on the NCCN categories please refer to the NCCN Compendium® at www.nccn.org). Reports vary according to regional differences, e.g. EU reports list EU-approved therapy options to support clinical
decision-making.^ǁ40

When using different Foundation Medicine services across the patient journey, consistency of the reports aid comparison of the results.^40,41